T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies
Public ClinicalTrials.gov record NCT01163201. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Optimization of the T Regulatory Cell and T Effector Cell Doses in Recipients of Double UCB Transplantation for Treatment of Hematological Malignancies
Study identification
- NCT ID
- NCT01163201
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Masonic Cancer Center, University of Minnesota
- Other
- Enrollment
- Not listed
Conditions and interventions
Conditions
- Acute Lymphocytic Leukemia
- Acute Myeloid Leukemia
- Anemia, Refractory, With Excess of Blasts
- Burkitt's Lymphoma
- Chronic Lymphocytic Leukemia
- Chronic Myelogenous Leukemia in Blast Crisis
- Chronic Myeloproliferative Disease
- Follicular Lymphoma
- Hematologic Malignancy
- High Grade Non-Hodgkin's Lymphoma
- Large Cell Non-Hodgkin's Lymphoma
- Lymphoblastic Lymphoma
- Lymphoplasmacytic Lymphoma
- Mantle-Cell Lymphoma
- Marginal Zone B-cell Lymphoma
- Prolymphocytic Lymphoma
- Small Lymphocytic Lymphoma
Interventions
- CD3+ Teff cells Biological
- Cyclophosphamide Drug
- Fludarabine Drug
- Total body irradiation Radiation
- Treg cells Biological
- Umbilical cord blood transplantation Biological
Biological · Drug · Radiation
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 31, 2013
- Primary completion
- Dec 31, 2014
- Completion
- Dec 31, 2014
- Last update posted
- Dec 1, 2017
2014 – 2015
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Masonic Cancer Center, University of Minnesota | Minneapolis | Minnesota | 55445 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01163201, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 1, 2017 · Synced May 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01163201 live on ClinicalTrials.gov.